Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Lamosyn 100 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Lamosyn 100

Approved

STANDARD

Lamosyn 100

Sun Pharmaceutical Industries Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 5e5e6304e4c61a86
Company: Sun Pharmaceutical Industries Limited
Type: Standard

Approval Details

Approval Id: 5e5e6304e4c61a86
Drug Approval Philippines Name: Lamosyn 100
Product Name: Lamosyn 100
Registration Number: DRP-16297
Brand Name: Lamosyn 100
Generic Name: Lamotrigine
Dosage Form: Tablet
Dosage Strength: 100 mg
Manufacturer: Sun Pharmaceutical Industries Limited
Importer: Sun Pharma Philippines, Inc.
Distributor: Sun Pharma Philippines, Inc.
Company Detail Path: /organization/sun-pharmaceutical-industries-limited
Issuance Date: 28 January 2025
Expiry Date: 28 January 2030
Pharmacologic Category: Anticonvulsant
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

5e5e6304e4c61a86

Type

Standard

Back to Philippines FDA Approvals